Abstract
Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have